Physician profile
William B Lamar
NPI 1073599601
$3,179.18
in general payments reported to CMS, 2019-2025
24 companies · $695 in 2025
The $695 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $258 · 2021: $372 · 2022: $278 · 2023: $509 · 2024: $834 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,035 · Education: $3.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,034.82 |
| Education | $3.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $765.09 | 2019-2023 | Krystexxa |
| Amgen INC. | $544.29 | 2024-2025 | Krystexxa, Tavneos, Uplizna |
| Astrazeneca Pharmaceuticals LP | $347.68 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $238.29 | 2019-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $204.48 | 2023-2025 | |
| Travere Therapeutics, INC. | $173.07 | 2023-2025 | Thiola |
| Akebia Therapeutics INC | $163.00 | 2020-2024 | Auryxia, Vafseo |
| Aurinia Pharma U.S., INC. | $111.96 | 2021-2025 | Lupkynis |
| Nxstage Medical, INC. | $85.48 | 2023 | Nxstage System One, Liberty Select Cycler |
| Calliditas Therapeutics US INC. | $73.04 | 2023-2025 | Tarpeyo |
| Vifor Pharma, INC. | $61.47 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.03 | 2024 | |
| Scpharmaceuticals INC. | $56.76 | 2025 | |
| Mallinckrodt Hospital Products INC. | $47.29 | 2020-2025 | Acthar |
| Daiichi Sankyo INC. | $43.60 | 2022-2023 | Injectafer |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $35.27 | 2023-2024 | Jardiance |
| Glaxosmithkline, LLC. | $29.80 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $24.61 | 2025 | Keveyis |
| Mozarc Medical US LLC | $23.26 | 2025 | Palindrome |
| Alexion Pharmaceuticals, INC. | $20.67 | 2021 | |
| Cycle Pharmaceuticals INC | $19.98 | 2025 | Venxxiva |
| Ani Pharmaceuticals, INC. | $19.64 | 2025 | Purified Cortrophin Gel |
| Apellis Pharmaceuticals, INC. | $16.86 | 2025 | Empaveli |
| Novo Nordisk INC | $14.56 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lamar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.